세계의 골다공증 치료제 시장 : 약제 클래스별, 투여 경로별, 유통 채널별, 최종 사용자별, 지역별 분석 및 예측(-2032년)

According to Stratistics MRC, the Global Osteoporosis Drugs Market is accounted for $16.3 billion in 2025 and is expected to reach $23.8 billion by 2032 growing at a CAGR of 5.5% during the forecast period. Osteoporosis drugs are medications designed to prevent, treat, or manage osteoporosis, a condition that weakens bones, making them fragile and prone to fractures. These drugs work by either slowing bone loss (anti-resorptive drugs) or promoting bone formation (anabolic drugs). Common classes include bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, parathyroid hormone analogs, and monoclonal antibodies. They help reduce fracture risk, improve bone density, and maintain skeletal strength. Prescribed based on factors like age, gender, fracture history, and bone mineral density, osteoporosis drugs are often combined with calcium, vitamin D, and lifestyle changes for optimal bone health and fracture prevention.

Market Dynamics:

Driver:

Rising Geriatric Population

The growing elderly population is a major driver of growth in the osteoporosis medicine market. There is a growing need for efficient treatments as osteoporosis becomes more likely as people age because of a decrease in bone density. The market is growing as a result of older individuals' increased access to and understanding of healthcare. Furthermore, improvements in medication formulations and customized therapies address the unique requirements of senior citizens. The market is expected to increase steadily as governments and healthcare providers place a greater emphasis on bone health, which will benefit patients as well as pharmaceutical businesses.

Restraint:

High Cost of Osteoporosis Drugs

The high cost of osteoporosis drugs significantly hampers market growth by limiting patient access and adherence to treatment. Many individuals, especially in low- and middle-income regions, struggle with affordability, leading to lower demand and increased disease burden. Additionally, high prices strain healthcare budgets and insurance systems, discouraging widespread adoption. This financial barrier restricts market expansion, slows innovation uptake, and forces patients to seek alternative or less effective treatment options.

Opportunity:

Advancements in Drug Development

Advancements in drug development are significantly driving the osteoporosis drugs market by introducing innovative therapies with improved efficacy and safety. Breakthroughs in biologics, monoclonal antibodies, and novel drug formulations are enhancing patient outcomes, reducing fracture risks, and improving bone density. Cutting-edge research in targeted treatments and personalized medicine is expanding the market potential. Additionally, regulatory approvals for next-generation osteoporosis drugs and increased R&D investments are accelerating market growth, offering new hope for millions suffering from osteoporosis worldwide.

Threat:

Side Effects & Safety Concerns

Side effects and safety concerns significantly hinder the growth of the osteoporosis drugs market. Adverse effects such as gastrointestinal issues, cardiovascular risks, and atypical fractures deter patient compliance and physician prescriptions. Safety warnings and regulatory scrutiny further limit drug adoption, impacting sales. Negative publicity and lawsuits also erode consumer trust. These challenges drive demand for alternative treatments, restricting market expansion and affecting pharmaceutical companies' revenue streams.

Covid-19 Impact:

The COVID-19 pandemic disrupted the osteoporosis drugs market by delaying diagnosis and treatment due to healthcare facility closures and reduced patient visits. Supply chain disruptions affected drug availability, while economic uncertainties limited patient affordability. However, increased telemedicine adoption and awareness of bone health during lockdowns supported market recovery. Post-pandemic, the market rebounded as healthcare services resumed, driving demand for osteoporosis treatments.

The parathyroid hormone (PTH) analogs segment is expected to be the largest during the forecast period

The parathyroid hormone (PTH) analogs segment is expected to account for the largest market share during the forecast period due to its ability to stimulate bone formation rather than just slowing bone loss. These drugs, such as teriparatide and abaloparatide, are particularly beneficial for high-risk fracture patients, enhancing bone density and reducing fracture risk. Increased awareness, rising osteoporosis prevalence, and favorable reimbursement policies are further boosting demand. Additionally, ongoing R&D efforts and technological advancements in drug delivery systems are expanding the market presence.

The hospitals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals segment is predicted to witness the highest growth rate as hospitals provide advanced diagnostic tools like bone density scans, facilitating early detection and personalized treatment plans. Additionally, specialized healthcare professionals enhance patient education and medication compliance, improving outcomes. The increasing prevalence of osteoporosis, coupled with hospitals' ability to offer comprehensive care, fosters higher drug demand. Moreover, collaborations with pharmaceutical companies support research and innovation, further expanding market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to advancements in drug formulations. Increased awareness, government initiatives, and improved healthcare access further propel market expansion. Pharmaceutical companies are innovating with biologics and anabolic treatments, enhancing patient outcomes. The market positively impacts public health by reducing fracture risks and improving quality of life. With continuous R&D and strategic collaborations, the sector fosters medical advancements, ensuring long-term benefits for patients and healthcare systems.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR due to increasing healthcare investments. Governments and healthcare providers are prioritizing osteoporosis management, leading to improved accessibility to advanced treatments. Innovation in drug formulations and the adoption of biologics are enhancing patient outcomes. Additionally, lifestyle changes and urbanization are increasing the prevalence of osteoporosis, further propelling demand. This market expansion fosters economic growth, job creation, and advancements in pharmaceutical research across the region.

Key players in the market

Some of the key players in Osteoporosis Drugs Market include Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Radius Health, Inc., UCB S.A., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Cipla Inc., Daiichi Sankyo Company, Novo Nordisk A/S, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Bayer AG, Johnson & Johnson Services Inc., Sanofi and Bristol-Myers Squibb Company.

Key Developments:

In March 2025, Taiwan-based Formosa Pharmaceuticals announced an exclusive licensing agreement with Cipla Limited referred to as "Cipla" for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007).

In February 2025, Summit Therapeutics Inc. announced a clinical trial collaboration with Pfizer Inc. to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.

In February 2025, Alloy Therapeutics Inc. announced its latest strategic collaboration with Pfizer Inc., to develop a new platform that could enhance Pfizer's ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery technologies.

Drug Classes Covered:

• Bisphosphonates
• Selective Estrogen Receptor Modulators (SERMs)
• Parathyroid Hormone-Related Protein (PTHrP) Analogues
• Parathyroid Hormone (PTH) Analogs
• RANK Ligand (RANKL) Inhibitors
• Calcitonin
• Other Drug Classes

Routes of Administration Covered:

• Oral
• Injectable

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

End Users Covered:

• Hospitals
• Clinics
• Homecare Settings

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Osteoporosis Drugs Market, By Drug Class

• 5.1 Introduction
• 5.2 Bisphosphonates
  • 5.2.1 Alendronate
  • 5.2.2 Risedronate
• 5.3 Selective Estrogen Receptor Modulators (SERMs)
• 5.4 Parathyroid Hormone-Related Protein (PTHrP) Analogues
• 5.5 Parathyroid Hormone (PTH) Analogs
• 5.6 RANK Ligand (RANKL) Inhibitors
• 5.7 Calcitonin
• 5.8 Other Drug Classes

6 Global Osteoporosis Drugs Market, By Route of Administration

• 6.1 Introduction
• 6.2 Oral
• 6.3 Injectable

7 Global Osteoporosis Drugs Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Online Pharmacies

8 Global Osteoporosis Drugs Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Homecare Settings

9 Global Osteoporosis Drugs Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Amgen Inc.
• 11.2 Eli Lilly and Company
• 11.3 Merck & Co., Inc.
• 11.4 Novartis AG
• 11.5 Pfizer Inc.
• 11.6 GlaxoSmithKline plc
• 11.7 Radius Health, Inc.
• 11.8 UCB S.A.
• 11.9 Teva Pharmaceutical Industries Ltd.
• 11.10 F. Hoffmann-La Roche Ltd
• 11.11 Cipla Inc.
• 11.12 Daiichi Sankyo Company
• 11.13 Novo Nordisk A/S
• 11.14 Sun Pharmaceutical Industries Ltd.
• 11.15 AbbVie Inc.
• 11.16 Bayer AG
• 11.17 Johnson & Johnson Services Inc.
• 11.18 Sanofi
• 11.19 Bristol-Myers Squibb Company